Amar_a.ns (AMAR)
Amar_a.ns is related to 3 other symbols. To date we've encountered 5 releases involving Amar_a.ns.
Last Price: 20.25 (0.00) - 11/11/2008,
2:00am
- Open: N/A
- High: N/A
- Low: N/A
Amar_a.ns Options
- Amar_a.ns "Business Partners"
- Amar_a.ns Press Releases
- Amar_a.ns News
- Amar_a.ns Contact
- Amar_a.ns Related (via TRYNT)
Amar_a.ns "Business Partners"
A "business partner" is defined as a third party company that has co-released at least one press release with Amar_a.ns.
Amar_a.ns Press Releases
- Amarillo Biosciences, Inc.: ABI Outlines $5 Million Capital Raising Program to Complete Regulatory Approval of Oral Interferon (Trackbacks) (Backlinks), Tue, 26 Sep 2006 10:40:00 PDT
AMARILLO, TX (MARKET WIRE) Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that it has commenced an effort to raise up to $5 Million to complete clinical studies of its low-dose oral interferon. Successful completion of these studies is necessary for ABI to apply for FDA approval.
- Amarillo Biosciences, Inc.: Amarillo Biosciences Retains Hance, Scarborough, Wright, Woodward & Weisbart for Public Policy Representation (Trackbacks) (Backlinks), Wed, 13 Sep 2006 10:22:00 PDT
AMARILLO, TX (MARKET WIRE) Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has retained Hance, Scarborough, Wright, Woodward & Weisbart (HSWWW), an Austin, Texas based law firm, to represent ABI regarding federal and state governmental relations matters.
- Amarillo Biosciences, Inc. : Amarillo Biosciences Submits Investigational New Drug Application to Test Oral Interferon in Idiopathic Pulmonary Fibrosis (Trackbacks) (Backlinks), Fri, 7 Jul 2006 7:54:00 PDT
AMARILLO, TX (MARKET WIRE) Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it submitted an Investigational New Drug (IND) Application to the FDA to begin a study of orally delivered interferon alpha in 60 patients with idiopathic pulmonary fibrosis (IPF). These IPF patients will be enrolled from approximately six clinical sites in the US. The patients will be given interferon or placebo for four weeks to assess
- Amarillo Biosciences, Inc. : Amarillo Biosciences Reports on Annual Meeting and Issues Progress Report (Trackbacks) (Backlinks), Thu, 29 Jun 2006 8:30:00 PDT
AMARILLO, TX (MARKET WIRE) Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today issued a progress report after its annual shareholder's meeting. At the shareholder's meeting, which was held June 22, 2006, the following corporate developments were discussed:
- AMARILLO BIOSCIENCES, INC.: Amarillo Biosciences to Hold Annual Meeting on June 22, 2006 (Trackbacks) (Backlinks), Thu, 15 Jun 2006 5:00:00 PDT
AMARILLO, TX (MARKET WIRE) Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it will hold its annual shareholders' meeting at 10:00 a.m. CST on June 22, 2006 in Amarillo, Texas at the Days Inn, East 1701 E IH40.
Amar_a.ns News
- We have not detected any news yet.
Amar_a.ns Contact
Amarillo Biosciences, Inc. Investor Relations: Philippe Niemetz PAN Consultants, Ltd. Tel: 800-477-7570 Tel: 212-344-6464 Fax: 212-618-1276 e-mail:p.niemetz@panconsultants.com Joseph M. Cummins, DVM, PhD Amarillo Biosciences, Inc. Tel: 806-376-1741 x 13 Fax: 806-376-9301 e-mail:jcummins@amarbio.com
TRYNT Related
- Amar_a.ns (AMAR_a.NS)
- Amar Remedie (AMAR.BO)
- Amar Remedie (AMARSL.BO)
- Amarillo Biosciences (AMAR.OB)
What is a Stock Cloud?
A Stock Cloud is a tag cloud like display of stock ticker symbols. The larger the ticker symbol the more frequent that company distributes press releases.